AT-Diabetic-i131	
    			    			
                ATLABi015-A            
            
        General
| Cell Line | |
| hPSCreg name | ATLABi015-A | 
| Cite as: | ATLABi015-A | 
| Alternative name(s) | 
	AT-Diabetic-i131	 | 
| Cell line type | Human induced pluripotent stem cell (hiPSC) | 
| Similar lines |  | 
| Last update | 30th September 2021 | 
| User feedback | |
| Provider | |
| Generator | IMCB, Adrian Teo's Lab (ATLAB) 
    									Contact:
    									 IMCB, Adrian Teo's Lab (ATLAB) | 
| Owner | IMCB, Adrian Teo's Lab (ATLAB) | 
| Distributors | |
| Derivation country | Singapore | 
| External Databases | |
| BioSamples | SAMEA9726684 | 
| General Information | |
| * Is the cell line readily obtainable for third parties? | Yes Research use: allowed Clinical use: not allowed Commercial use: allowed | 
Donor Information
| General Donor Information | |
| Sex | male | 
| Age of donor (at collection) | 75-79 | 
| Ethnicity | Asian Chinese | 
| Phenotype and Disease related information (Donor) | |
| Diseases | A disease was diagnosed. | 
| Karyotyping (Donor) | |
| Has the donor karyotype been analysed? | Yes 
												46, XY
											 
											Karyotyping method:
											G-Banding											
																						 | 
| Other Genotyping (Donor) | |
| Is there genome-wide genotyping or functional data available? | No | 
| External Databases (Donor) | |
| BioSamples | SAMEA10201995 | 
Ethics
| Has informed consent been obtained from the donor of the embryo/tissue from which the pluripotent stem cells have been derived? | Yes | 
| Was the consent voluntarily given? | Yes | 
| Has the donor been informed that participation will not directly influence their personal treatment? | Yes | 
| Can you provide us with a copy of the Donor Information Sheet provided to the donor? | No | 
| Do you (Depositor/Provider) hold the original Donor Consent Form? | No | 
| If you do not hold the Donor Consent Form, do you know who does? | Yes | 
| Alternatives to consent are available? | No | 
| Confirm that consent was obtained by a qualified professional | Yes | 
| Has the donor been informed about how her/his data will be protected? | Yes | 
| Please indicate whether the data associated with the donated material has been pseudonymised or anonymised. | pseudonymised | 
| Does consent explicitly allow the derivation of pluripotent stem cells? | Yes | 
| Does consent prevent CELLS DERIVED FROM THE DONATED BIOSAMPLE from being made available to researchers anywhere in the world? | No | 
| How may genetic information associated with the cell line be accessed? | Controlled Access | 
| Will the donor expect to receive financial benefit, beyond reasonable expenses, in return for donating the biosample? | No | 
| Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the Research Protocol including the consent provisions? | Yes | 
| Name of accrediting authority involved? | NHG DSRB | 
| Approval number | 2013/00937 | 
| Do you have obligations to third parties in regard to the use of the cell line? | Yes | 
| Please describe: | |
| For generation of the cell line, who was the supplier of any recombined DNA vectors or commercial kits used? | In consultation with clinician collaborator | 
hIPSC Derivation
| General | |
| Source cell type | |
| Age of donor (at collection) | 75-79 | 
| Reprogramming method | |
| Vector type | Non-integrating | 
| Vector | Episomal | 
| Vector free reprogramming | |
| Type of used vector free reprogramming factor(s) | 
	None	 | 
| Other | |
| Derived under xeno-free conditions | Unknown | 
| Derived under GMP? | No | 
| Available as clinical grade? | No | 
Culture Conditions
| Surface coating | Gelatin / MEF media | ||||||
| Feeder cells | No | ||||||
| Passage method | Mechanically | ||||||
| CO2 Concentration | 5 % | ||||||
| Medium | TeSR™ E8™ Supplements 
 | ||||||
| Has Rock inhibitor (Y27632) been used at passage previously with this cell line? | Unknown | ||||||
| Has Rock inhibitor (Y27632) been used at cryo previously with this cell line? | No | ||||||
| Has Rock inhibitor (Y27632) been used at thaw previously with this cell line? | Unknown | 
Characterisation
Analysis of Undifferentiated Cells
| Marker | Expressed | Immunostaining | RT-PCR | Flow Cytometry | Enzymatic Assay | Expression Profiles | 
| POU5F1 (OCT-4) | Yes | |||||
| SOX2 | Yes | |||||
| NANOG | Yes | 
							Score: 						
												| Marker | Present | Absent | 
| mCpG | ||
| OCT4 | 
Differentiation Potency
Genotyping
| Karyotyping (Cell Line) | |
| Has the cell line karyotype been analysed? | Yes 
												46, XY
											 
											Karyotyping method:
											G-Banding											
																						 | 
| Other Genotyping (Cell Line) | |

Login to share your feedback, experiences or results with the research community.